专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5000959A Liposome composition and production thereof 失效
标题翻译：脂质体组成及其生产
公开(公告)号：US5000959A
公开(公告)日：1991-03-19
申请号：US350029
申请日：1989-05-10
申请人： Katsumi Iga , Naoru Hamaguchi , Yasuaki Ogawa
发明人： Katsumi Iga , Naoru Hamaguchi , Yasuaki Ogawa
IPC分类号： A61K9/10 , A61K9/127 , A61K47/24 , A61K47/26
CPC分类号： A61K9/1271
摘要： The liposome compositions entrapping a drug are prepared by constituting the liposomal membrane with a saturated phospholipid and a glycolipid having sialic acid group. Thus obtained compositions circulate stably in blood for a long time after intravenous administration.
摘要翻译：包埋药物的脂质体组合物通过用饱和磷脂和具有唾液酸基团的糖脂构成脂质体膜来制备。这样得到的组合物在静脉内给药后长时间在血液中稳定地循环。

2. 发明授权

US4877561A Method of producing liposome 失效
标题翻译：生产脂质体的方法
公开(公告)号：US4877561A
公开(公告)日：1989-10-31
申请号：US33498
申请日：1987-04-02
申请人： Katsumi Iga , Naoru Hamaguchi , Yasuaki Ogawa
发明人： Katsumi Iga , Naoru Hamaguchi , Yasuaki Ogawa
IPC分类号： B01J13/02 , A61K9/10 , A61K9/127
CPC分类号： A61K9/1277 , Y10S436/829 , Y10S514/885 , Y10T428/2984
摘要： Liposomes with an increased drug trap can be prepared by adding a readily volatile organic solvent to a drug-containing liquid with liposomes dispersed therein to cause gel formation and then removing said organic solvent by evaporation.
摘要翻译：具有增加的药物捕获剂的脂质体可以通过将易挥发的有机溶剂加入含有分散在其中的脂质体的含药液体中以引起凝胶形成，然后通过蒸发除去所述有机溶剂来制备。

3. 发明授权

US4844904A Liposome composition 失效
标题翻译：脂质体组成
公开(公告)号：US4844904A
公开(公告)日：1989-07-04
申请号：US933619
申请日：1986-11-21
申请人： Naoru Hamaguchi , Katsumi Iga , Yasuaki Ogawa
发明人： Naoru Hamaguchi , Katsumi Iga , Yasuaki Ogawa
IPC分类号： A61K9/127
CPC分类号： A61K9/1277 , Y10S436/829 , Y10S514/885 , Y10T428/2984
摘要： Liposome compositions in which a drug is retained in stable condition are prepared by dispersing liposomes obtained by removal of a solvent from a drug-containing w/o emulsion in an aqueous solution having an osmotic pressure higher by at least 20 percent than the osmotic pressure of a solution used for entrapping the drug in said liposomes. This composition is conducive to a sustained therapeutic efficacy or a better delivery of the drug to a target organ.
摘要翻译：其中药物保持在稳定状态的脂质体组合物通过将通过从含药物的w / o乳液中除去溶剂获得的脂质体分散在渗透压高于渗透压至少20％的渗透压的水溶液中来制备用于将药物包埋在所述脂质体中的溶液。该组合物有利于持续的治疗功效或更好地将药物递送至靶器官。

4. 发明授权

US5080904A Liposome composition and its production 失效
标题翻译：脂质体组成及其生产
公开(公告)号：US5080904A
公开(公告)日：1992-01-14
申请号：US350030
申请日：1989-05-10
申请人： Katsumi Iga , Naoru Hamaguchi , Yasuaki Ogawa
发明人： Katsumi Iga , Naoru Hamaguchi , Yasuaki Ogawa
IPC分类号： A61K9/10 , A61K9/127 , A61K38/20
CPC分类号： A61K38/2013 , A61K9/1271
摘要： The liposome compositions entrapping a drug are prepared by constituting the liposomal membrane with a saturated phospholipid and a glycolipid having sulfo group. Thus obtained compositions circulate stably in blood for a long time after intravenous administration.
摘要翻译：通过用饱和磷脂和具有磺基的糖脂构成脂质体膜来制备包埋药物的脂质体组合物。这样得到的组合物在静脉内给药后长时间在血液中稳定地循环。

5. 发明授权

US5019394A Liposome composition and its production 失效
标题翻译：脂质体组成及其制备
公开(公告)号：US5019394A
公开(公告)日：1991-05-28
申请号：US159945
申请日：1988-02-24
申请人： Naoru Hamaguchi , Katsumi Iga , Yasuaki Ogawa
发明人： Naoru Hamaguchi , Katsumi Iga , Yasuaki Ogawa
IPC分类号： A61K9/127
CPC分类号： A61K9/1272 , Y10S514/885 , Y10T428/2984
摘要： The liposome compositions entrapping a drug are prepared by constituting the liposomal membrane with saturated phospholipids and anionic surfactants of high Krafft point at concentrations above their critical micelle concentrations. Thus obtained compositions circulate stably in blood for a long time after intravenous administration.

6. 发明授权

US5252336A Liposome composition whose liposome membrane contains a polyoxyethylene derivative 失效
标题翻译：脂质体组成的脂质体膜含有聚氧乙烯衍生物
公开(公告)号：US5252336A
公开(公告)日：1993-10-12
申请号：US687918
申请日：1991-06-05
申请人： Katsumi Iga , Kazuhiro Ohkouchi , Yasuaki Ogawa
发明人： Katsumi Iga , Kazuhiro Ohkouchi , Yasuaki Ogawa
IPC分类号： A61K9/127 , B01J13/02
CPC分类号： A61K9/1272 , Y10S436/829 , Y10T428/2984
摘要： A liposome composition is obtained by using as constituent components of the liposome membrane a polyoxyethylene derivative represented by the general formula:X--O--(CH.sub.2 CH.sub.2 O).sub.n --Y (I)wherein X represents an alkanoyl group or an alkyl group, Y represents a residue of a compound having a negative charge, and n is an integer of 2 to 50, and a phospholipid. The liposome composition has good dispersibility, high drug-encapsulation property and high stability.
摘要翻译： PCT No.PCT / JP91 / 00481 Sec。 371日期1991年6月5日 102（e）1991年6月5日PCT 1991年4月12日提交PCT公布。出版物WO91 / 16040 1991年10月31日。脂质体组合物通过以脂质体膜的构成成分作为通式XO-（CH 2 CH 2 O）n Y（I）表示的聚氧乙烯衍生物，其中X表示烷酰基或烷基， Y表示具有负电荷，n为2〜50的整数的化合物的残基和磷脂。脂质体组成具有良好的分散性，高的药物包封性和高稳定性。

7. 发明授权

US5094854A Liposome composition useful for hypertheria therapy 失效
标题翻译：脂质体组合物可用于治疗高血压
公开(公告)号：US5094854A
公开(公告)日：1992-03-10
申请号：US607647
申请日：1990-10-31
申请人： Yasuaki Ogawa , Katsumi Iga , Yasutaka Igari
发明人： Yasuaki Ogawa , Katsumi Iga , Yasutaka Igari
IPC分类号： A61K9/127 , A61K9/133
CPC分类号： A61K9/1277 , A61K9/127 , A61K9/1272 , Y10S514/963 , Y10T428/2984
摘要： This invention relates to the liposome compositions which are characterized in that the phase transition temperature of the membrane is in the range of 40.degree. to 45.degree. C. and the osmotic pressure of a drug-containing solution to be entrapped in liposomes is 1.2 to 2.5 times higher than that of body fluid of warm-blooded animals. The compositions are useful for treatment of solid tumors in hyperthermia therapy.

8. 发明授权

US5993848A Dissolution liquid for drug in iontophoresis 失效
标题翻译：药物溶出液在离子电渗疗法中的应用
公开(公告)号：US5993848A
公开(公告)日：1999-11-30
申请号：US659372
申请日：1996-06-06
申请人： Yasuyuki Suzuki , Katsumi Iga , Yukihiro Matsumoto
发明人： Yasuyuki Suzuki , Katsumi Iga , Yukihiro Matsumoto
IPC分类号： A61N1/30 , A61K31/785 , A61F13/00
CPC分类号： A61N1/30
摘要： A drug held or supported by an interface comprising a porous matrix is dissolved with a drug dissolution liquid containing a humectant, and the drug is transdermally delivered by iontophoresis. The humectant includes e.g. glycerin and other polyhydric alcohols, sugar alcohols, proline and other amino acids and acidic mucopolysaccharides. The concentration of the humectant may be about 1 to 50% by weight, and the concentration of proline or other amino acid or its salt may be about 1 to 30% by weight. The drug includes (1) a physiologically active peptide or protein with a molecular weight of 100 to 30,000 or (2) a nonpeptide physiologically active compound with a molecular weight of 100 to 1,000.
摘要翻译：由包含多孔基质的界面保持或负载的药物与含有保湿剂的药物溶解液溶解，并且通过离子电渗法透皮递送药物。保湿剂包括例如甘油等多元醇，糖醇，脯氨酸等氨基酸和酸性粘多糖。保湿剂的浓度可以为约1至50重量％，脯氨酸或其它氨基酸或其盐的浓度可以为约1至30重量％。药物包括（1）分子量为100〜30,000的生理活性肽或蛋白质，或（2）分子量为100〜1,000的非肽生理活性化合物。

9. 发明申请

US20090264521A1 Percutaneous absorption preparation 审中-公开
标题翻译：经皮吸收制剂
公开(公告)号：US20090264521A1
公开(公告)日：2009-10-22
申请号：US12457772
申请日：2009-06-22
申请人： Yasuyuki Suzuki , Katsumi Iga , Masaomi Miyamoto
发明人： Yasuyuki Suzuki , Katsumi Iga , Masaomi Miyamoto
IPC分类号： A61K31/343
CPC分类号： A61K9/7061 , A61K9/0014 , A61K31/343 , A61K31/4355 , A61K45/06 , A61K47/10 , A61K47/14 , A61K47/18 , C07D307/93
摘要： Percutaneous absorption preparations which make it possible to absorb compounds having a melatonin receptor agonist activity via a convenient administration system, have favorable blood-drug-concentration-time profile and can exert a therapeutic effect on a disease caused by a decrease in secretion of melatonin at night.
摘要翻译：能够通过便利的给药系统吸收具有褪黑激素受体激动剂活性的化合物的经皮吸收制剂具有有利的血药浓度 - 时间特征，并且可以对由褪黑激素分泌减少引起的疾病发挥治疗作用晚。

10. 发明授权

US5750100A Sustained releasable parenteral pharmaceutical preparations and method of producing the same 失效
标题翻译：持续可释放的肠胃外药物制剂及其制备方法
公开(公告)号：US5750100A
公开(公告)日：1998-05-12
申请号：US734636
申请日：1996-10-21
申请人： Yutaka Yamagata , Katsumi Iga , Hiroaki Okada
发明人： Yutaka Yamagata , Katsumi Iga , Hiroaki Okada
IPC分类号： A61K9/14 , A61K9/00 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/26 , A61K9/70 , A61K38/00 , A61K38/20 , A61K38/21 , A61K38/28 , A61K47/14 , A61K38/02
CPC分类号： A61K9/2013 , A61K38/2013 , A61K38/212 , A61K38/28 , A61K9/1617 , A61K9/70 , A61K9/0024
摘要： A parenteral pharmaceutical preparation comprises a matrix containing a physiologically active peptide or protein and a polyglycerol diester of a saturated fatty acid, and the matrix is in a solid form at room temperature. The molecular weight of the physiologically active peptide or protein is 2,000 dalton or more. The saturated fatty acid includes fatty acids having about 16 to 30 carbon atoms such as palmitic acid, stearic acid, etc. The matrix may be in a pillar or granular form. The parenteral pharmaceutical preparation can be used as an injectable solid administered subcutaneously or intramuscularly (for example, a pellet or tablet for implantation), a suppository or the like, and can release the physiologically active peptide or protein sustainedly for a prolonged period of one week or more.
摘要翻译：肠胃外药物制剂包含含有生理活性肽或蛋白质的基质和饱和脂肪酸的聚甘油二酯，并且所述基质在室温下为固体形式。生理活性肽或蛋白质的分子量为2,000道尔顿或更多。饱和脂肪酸包括具有约16至30个碳原子的脂肪酸，例如棕榈酸，硬脂酸等。基质可以是柱状或颗粒形式。肠胃外药物制剂可以用作皮下或肌肉内给药的可注射固体（例如，用于植入的丸粒或片剂），栓剂等，并且可以持续释放生理活性肽或蛋白质一周的长时间或者更多。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式